A Novel Biomarker Panel Examining Response to Gemcitabine with or Without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jan 26

PMID 26808546

Citations 8

Authors

David B Shultz

Jonathan Pai

Wayland Chiu

Kendall Ng

Madeline G Hellendag

Gregory Heestand

Daniel T Chang

Dongsheng Tu

Malcolm J Moore

Wendy R Parulekar

Albert C Koong

Affiliations

Soon will be listed here.

Abstract

Purpose: NCIC Clinical Trials Group PA.3 was a randomized control trial that demonstrated improved overall survival (OS) in patients receiving erlotinib in addition to gemcitabine for locally advanced or metastatic pancreatic cancer. Prior to therapy, patients had plasma samples drawn for future study. We sought to identify biomarkers within these samples.

Experimental Design: Using the proximity ligation assay (PLA), a probe panel was built from commercially available antibodies for 35 key proteins selected from a global genetic analysis of pancreatic cancers, and used to quantify protein levels in 20 uL of patient plasma. To determine if any of these proteins levels independently associated with OS, univariate and mulitbaraible Cox models were used. In addition, we examined the associations between biomarker expression and disease stage at diagnosis using Fisher's exact test. The correlation between Erlotinib sensitivity and each biomarkers was assessed using a test of interaction between treatment and biomarker.

Results And Conclusion: Of the 569 eligible patients, 480 had samples available for study. Samples were randomly allocated into training (251) and validation sets (229). Among all patients, elevated levels of interleukin-8 (IL-8), carcinoembryonic antigen (CEA), hypoxia-inducible factor 1-alpha (HIF-1 alpha), and interleukin-6 were independently associated with lower OS, while IL-8, CEA, platelet-derived growth factor receptor alpha and mucin-1 were associated with metastatic disease. Patients with elevated levels of receptor tyrosine-protein kinase erbB-2 (HER2) expression had improved OS when treated with erlotinib compared to placebo. In conclusion, PLA is a powerful tool for identifying biomarkers from archived, small volume serum samples. These data may be useful to stratify patient outcomes regardless of therapeutic intervention.

Trial Registration: ClinicalTrials.gov NCT00040183.

Citing Articles

Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapy.

Zhao A, Tu D, He Y, Liu L, Wu B, Ren Y Front Genet. 2025; 15:1497254.

PMID: 39741907 PMC: 11685217. DOI: 10.3389/fgene.2024.1497254.

Unveiling the Promise: Navigating Clinical Trials 1978-2024 for PDAC.

Dominguez A, Perz M, Xu Y, Cedillo L, Huang O, McIntyre C Cancers (Basel). 2024; 16(21).

PMID: 39518005 PMC: 11544830. DOI: 10.3390/cancers16213564.

The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials.

Siolas D, Morrissey C, Oberstein P J Pancreatol. 2020; 3(3):121-131.

PMID: 33133736 PMC: 7595263. DOI: 10.1097/JP9.0000000000000052.

Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.

Strapcova S, Takacova M, Csaderova L, Martinelli P, Lukacikova L, Gal V Cancers (Basel). 2020; 12(8).

PMID: 32707920 PMC: 7464147. DOI: 10.3390/cancers12082005.

The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis.

Han S, Huang T, Hou F, Yao L, Wang X, Wu X Ther Adv Med Oncol. 2019; 11:1758835919875851.

PMID: 31579115 PMC: 6759726. DOI: 10.1177/1758835919875851.

References

Koom W, Seong J, Kim Y, Pyun H, Song S . CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008; 73(4):1148-54. DOI: 10.1016/j.ijrobp.2008.06.1483. View

Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P . Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012; 106(6):1033-8. PMC: 3304403. DOI: 10.1038/bjc.2012.18. View

Chang S, Zahn J, Horecka J, Kunz P, Ford J, Fisher G . Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med. 2009; 7:105. PMC: 2796647. DOI: 10.1186/1479-5876-7-105. View

Schaefer G, Shao L, Totpal K, Akita R . Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res. 2007; 67(3):1228-38. DOI: 10.1158/0008-5472.CAN-06-3493. View

Stock A, Hahn S, Troost G, Niggemann B, Zanker K, Entschladen F . Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation. Exp Cell Res. 2014; 326(2):307-14. DOI: 10.1016/j.yexcr.2014.04.022. View

Vainshtein J, Schipper M, Zalupski M, Lawrence T, Abrams R, Francis I . Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose.... Int J Radiat Oncol Biol Phys. 2012; 86(1):96-101. PMC: 3646633. DOI: 10.1016/j.ijrobp.2012.11.020. View

Klinkenbijl J, Jeekel J, Sahmoud T, van Pel R, Couvreur M, Veenhof C . Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 2000; 230(6):776-82; discussion 782-4. PMC: 1420941. DOI: 10.1097/00000658-199912000-00006. View

Micke O, Bruns F, Schafer U, Kurowski R, Horst E, Willich N . CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2003; 23(2A):835-40. View

Lang S, Moser C, Gaumann A, Klein D, Glockzin G, Popp F . Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces.... Clin Cancer Res. 2007; 13(21):6459-68. DOI: 10.1158/1078-0432.CCR-07-1104. View

10.

Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, Ko S . Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 2004; 23(6C):4721-7. View

11.

Colbert L, Fisher S, Balci S, Saka B, Chen Z, Kim S . High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2015; 91(3):631-9. PMC: 5746186. DOI: 10.1016/j.ijrobp.2014.11.004. View

12.

Chen Y, Shi M, Yu G, Qin X, Jin G, Chen P . Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol. 2012; 18(10):1123-9. PMC: 3296988. DOI: 10.3748/wjg.v18.i10.1123. View

13.

Haas M, Heinemann V, Kullmann F, Laubender R, Klose C, Bruns C . Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013; 139(4):681-9. DOI: 10.1007/s00432-012-1371-3. View

14.

Fredriksson S, Dixon W, Ji H, Koong A, Mindrinos M, Davis R . Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat Methods. 2007; 4(4):327-9. DOI: 10.1038/nmeth1020. View

15.

Dumitra S, Jamal M, Aboukhalil J, Doi S, Chaudhury P, Hassanain M . Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score. HPB (Oxford). 2013; 15(12):1002-9. PMC: 3843620. DOI: 10.1111/hpb.12085. View

16.

Barrett T, Troup D, Wilhite S, Ledoux P, Rudnev D, Evangelista C . NCBI GEO: mining tens of millions of expression profiles--database and tools update. Nucleic Acids Res. 2006; 35(Database issue):D760-5. PMC: 1669752. DOI: 10.1093/nar/gkl887. View

17.

Kitamoto S, Yokoyama S, Higashi M, Yamada N, Takao S, Yonezawa S . MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors. Oncogene. 2012; 32(39):4614-21. DOI: 10.1038/onc.2012.478. View

18.

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

19.

Sahraei M, Roy L, Curry J, Teresa T, Nath S, Besmer D . MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene. 2012; 31(47):4935-45. PMC: 3337953. DOI: 10.1038/onc.2011.651. View

20.

Harsha H, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S . A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009; 6(4):e1000046. PMC: 2661257. DOI: 10.1371/journal.pmed.1000046. View